Shots:
- Daiichi Sankyo has dosed the first patient with DS3610 in P-I trial for the treatment of advanced, metastatic or unresectable solid tumors
- The P-I trial will evaluate DS-3610 in advanced or metastatic solid tumors to determine the recommended dose, assessing PK & immunogenicity endpoints plus safety endpoints incl. DLTs & AEs. Exploratory endpoints like ORR, DCR, DoR, time to response, PFS & OS will also be assessed
- DS-3610 is a STING agonist ADC that uses a monoclonal antibody with novel Fc modifications to deliver a STING-activating payload directly to tumors, inducing immune-mediated cancer cell targeting
Ref: Daiichi Sankyo | Image: Daiichi Sankyo| Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
